Health Care · Biological Products, (No Diagnostic Substances)

FATE FATE THERAPEUTICS INC SEC Filings & Insider Trading Activity 2026

company
CIK 1434316107 filings
Russell 2000

FATE at a glance

FATE THERAPEUTICS INC (FATE, SEC CIK 1434316) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), FATE THERAPEUTICS INC (FATE) reported revenue of $6.6 million (down 51.2% from FY2024) and a net loss of $136.3 million. Diluted EPS was -$1.15.
  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding FATE THERAPEUTICS INC (FATE) shares worth $81.2 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Adawi Kamal on November 3, 2026 of 6,582 shares at $2.05 per share.
  • In the last 90 days, FATE insiders reported 0 open-market purchases ($0) and 1 open-market sale ($14K) on Form 4, a net sale of $14K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$6.6M
−51.2% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$14K
13F holders
21 funds
$81.2M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly collaboration revenue $0 vs $1.7M YoY, following Ono performance-obligation completion
  • R&D expense $24.2M vs $25.8M YoY, G&A expense $8.0M vs $10.6M
  • Best-performing area: clinical trials, expense increase $2.4M YoY; laboratory materials expense decrease $1.5M
  • Cash, cash equivalents and short-term investments $139.1M; operating cash used $82.1M
  • Outlook: funding sufficient for at least twelve months; $15.0M CIRM grant pending agreement and milestones, additional capital expected sep

Risk Factors

  • Newly added clinical-operations risk triggered by September 2026 CAR-T trial suspensions after fatal immune effector cell-associated hemophagocytic syndrome cases
  • Most materially updated regulatory risk: RECLAIM-LN Phase 2 design may require additional patients, trials, or safety data before FT819 approval
  • Manufacturing compliance risk: FDA CDRP participation may not accelerate FT819 development or manufacturing readiness
  • Operational risk: limited investigator CAR-T experience could cause delayed adverse-event recognition and inconsistent safety reporting
  • Competitive risk: increased autoimmune cell-therapy trials are intensifying competition for eligible patients and investigators

AI summary of the FATE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Fate Therapeutics’ financial results for quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed financial results for investor review

Item EX-99.1: Item EX-99.1

  • Q3 net loss $30.7M, or $0.25 per share, versus $32.3M, or $0.27, in Q3 2025
  • Cash, equivalents and investments $139.1M, with $15.0M CIRM grant extending runway to mid-2028
Filed Nov 5, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • ATM equity program authorizes up to $100 million in common-stock sales, providing Fate with flexible funding access
  • Share issuance remains discretionary, limiting immediate dilution but creating potential dilution if capital is raised

Item 1.02: Termination of a Material Definitive Agreement

  • Jefferies ATM agreement terminated November 5, 2026, replaced in connection with a new Sales Agreement
  • 2,801,602 shares sold for $8.0 million gross proceeds under the terminated facility
Filed Sep 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • $15.0M CIRM CLIN2 grant supports RECLAIM-LN, reducing Fate’s funding burden for FT819’s lupus nephritis development
  • RECLAIM-LN is a Phase 2 potentially registrational trial targeting approximately 53 refractory patients

Item 8.01: Other Events

  • CIRM awarded Fate Therapeutics a $15 million grant on September 25, 2026
  • Funding supports Phase 2 RECLAIM-LN clinical trial of FT819

AI summaries of FATE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for FATE

Don't miss the next FATE filing

  • Alerts as it files. A push when FATE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut FATE, by share count.
  • Ask anything. An AI agent that reads every FATE filing and answers with sources.

FATE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Adawi KamalSellNov 3, 2026$2.05
TAHL CINDYSellAug 4, 2026$2.46
Valamehr BahramSellAug 4, 2026$2.46
Xu YuanAJun 12, 2026-
Lee Michael StewartAJun 12, 2026-
RASTETTER WILLIAM HAJun 12, 2026-
Redmile Group, LLCAJun 12, 2026-
EPSTEIN ROBERT SAJun 12, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$13.6M$6.6M
Operating Income--$210.3M-$147.7M
Net Income-$160.9M-$186.3M-$136.3M
Op. Margin--1542.6%-2222.4%
Net Margin--1366.5%-2051.1%
Balance Sheet
Total Assets$506.2M$440.7M$318.9M
Equity-$318.7M$207.2M
ROE--58.4%-65.8%
Per Share
EPS$-1.64$-1.64$-1.15
Cash Flow
Operating CF--$122.9M-$106.1M
CapEx$6.2M$730K$6.0M

Source: XBRL data in FATE THERAPEUTICS INC (FATE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate FATE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
FATE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$81.2M
Q2 202622$102.5M
Q1 202623$47.3M
Q4 202523$36.5M
Q3 202524$46.8M
Q2 202526$48.3M
Q1 202523$27.5M
Q4 202421$46.9M
Position changes: Q2 2026 → Q3 2026
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

FATE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KNov 5, 2026Analysis-
4Nov 4, 2026--
8-KSep 28, 2026Analysis-
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
4Aug 5, 2026--
4Aug 5, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 15, 2026Analysis-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 4, 2026Analysis
4May 21, 2026-
4May 21, 2026-
8-KMay 13, 2026Analysis
10-QMay 13, 2026Analysis
4May 7, 2026-

Related Health Care companies

All Health Care →

FATE SEC filings: frequently asked questions

Are FATE insiders buying or selling?

In the last 90 days, FATE THERAPEUTICS INC (FATE) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $13,525 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold FATE stock?

As of September 30, 2026, the largest FATE THERAPEUTICS INC (FATE) holders among the 13F filers tracked by SignalX were BlackRock ($16.8 million), Vanguard Portfolio Management LLC ($11.8 million), Vanguard Capital Management LLC ($10.7 million), Two Sigma Investments ($9.3 million), Johnson & Johnson ($8.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was FATE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), FATE THERAPEUTICS INC (FATE) reported revenue of $6.6 million (down 51.2% from FY2024) and a net loss of $136.3 million. Diluted EPS was -$1.15. The figures come from the XBRL data in the 10-K.

What did FATE report in its latest 8-K?

FATE THERAPEUTICS INC (FATE) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Fate Therapeutics’ financial results for quarter ended September 30, 2026.

What are the latest FATE SEC filings?

FATE THERAPEUTICS INC (FATE) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 4, 2026.

What is FATE's SEC CIK number?

FATE THERAPEUTICS INC (FATE)'s SEC Central Index Key (CIK) is 1434316. EDGAR lists every FATE filing under that number.

Ask anything about FATE

The research agent reads FATE's filings, financials, insider trades and 13F holders, then answers with sources.